Proteome systems names William Emhiser, a former Millipore executive, to head its North American operations
William C Emhiser has joined Proteome Systems as president of North American operations, according to Keith Williams, chief executive chairman and executive director.
Proteome Systems developes integrated proteomic technologies that speed discovery and is dedicated to the development of proteomics technology, to the discovery of biomarkers and drug targets, and to proteomic bioinformatics.
"Bill brings a wealth of life science industry experience to Proteome Systems and will play a vital role in commercialising our proteomics technology in one of our largest market segments.
I believe Bill will enable the company to translate our scientific expertise and existing position and success into a strong, sustainable North American business, and I'm excited he's joining our senior management team," said Williams.
Emhiser will manage Proteome Systems's North American subsidiary with a focus on bringing the full range of the company's tools and services to the scientific community while continuing to build the customer and technical support capabilities in the Woburn, Massachusetts facility.
He will also manage relationships with key strategic partners in North America, including Charles River Proteomics Services (a joint venture between Proteome Systems and Charles River Laboratories), Millipore, and Sigma.
With over 25 years of life science industry experience, Emhiser most recently served as president of the life science division of Millipore.
While there, he was instrumental in the creation of the division and positioning it into a high growth mode with over $100 million in revenues supplying biomolecular separation devices to the genomics, proteomics and drug discovery markets.
In this role, he launched over 25 new products and successfully completed several significant alliance partnerships.
Previously, Emhiser was the President of Amicon, successfully guiding the company through an acquisition by Millipore in 1996.
Prior to Amicon, he was president and chief operating officer of Gelman Sciences, now part of Pall.
